Sanjeev Kaul

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection
    S Kaul
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543 4000, USA
    Antimicrob Agents Chemother 45:758-63. 2001
  2. ncbi Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food
    Sanjeev Kaul
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb BMS Research and Development, Princeton, NJ 08543, USA
    Am J Health Syst Pharm 67:217-22. 2010
  3. ncbi Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects
    Bharat D Damle
    Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    J Clin Pharmacol 42:791-7. 2002
  4. ncbi Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads
    Bharat D Damle
    Department of Clinical Discovery, Biostatistics, and Data Management, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    J Clin Pharmacol 42:419-27. 2002
  5. ncbi Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects
    Ping Ji
    Bristol Myers Squibb Research and Development, Mail Stop E1215, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    J Clin Pharmacol 48:948-56. 2008
  6. ncbi Disposition of [1'-(14)C]stavudine after oral administration to humans
    Lian Zhou
    Department of Biotransformation, Bristol Myers Squibb Co, Princeton, NJ 088543, USA
    Drug Metab Dispos 38:655-66. 2010
  7. ncbi Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine
    Min Zhu
    Research and Development, Bristol Myers Squibb, P O Box 4000, Princeton, NJ 08543 4000, USA
    Antimicrob Agents Chemother 53:2346-53. 2009
  8. ncbi Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin
    Bharat D Damle
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    Antimicrob Agents Chemother 46:385-91. 2002
  9. ncbi The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease
    Jing-He Yan
    Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA
    J Clin Pharmacol 45:434-45. 2005
  10. ncbi Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole
    B Damle
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA
    Biopharm Drug Dispos 23:59-66. 2002

Collaborators

Detail Information

Publications11

  1. ncbi Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection
    S Kaul
    Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543 4000, USA
    Antimicrob Agents Chemother 45:758-63. 2001
    ....
  2. ncbi Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food
    Sanjeev Kaul
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb BMS Research and Development, Princeton, NJ 08543, USA
    Am J Health Syst Pharm 67:217-22. 2010
    ..The effect of mixing the contents of efavirenz capsules (sprinkles) with a small amount of food on the bioavailability and pharmacokinetics of efavirenz in healthy adults was evaluated...
  3. ncbi Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects
    Bharat D Damle
    Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    J Clin Pharmacol 42:791-7. 2002
    ..The pharmacokinetic profile of the enteric formulation appears to be similar in healthy and HIV-infected subjects...
  4. ncbi Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads
    Bharat D Damle
    Department of Clinical Discovery, Biostatistics, and Data Management, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    J Clin Pharmacol 42:419-27. 2002
    ..The clinical significance of such moderate reductions in didanosine exposure with food, especially as part of a highly active antiretroviral therapy, is not clear...
  5. ncbi Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects
    Ping Ji
    Bristol Myers Squibb Research and Development, Mail Stop E1215, Route 206 and Province Line Road, Princeton, NJ 08543, USA
    J Clin Pharmacol 48:948-56. 2008
    ..99 [0.85-1.15]; C(max), 1.05 [0.91, 1.22]). In summary, a 2-way pharmacokinetic interaction between efavirenz and carbamazepine was demonstrated in this study...
  6. ncbi Disposition of [1'-(14)C]stavudine after oral administration to humans
    Lian Zhou
    Department of Biotransformation, Bristol Myers Squibb Co, Princeton, NJ 088543, USA
    Drug Metab Dispos 38:655-66. 2010
    ..In conclusion, absorption and elimination of stavudine were rapid and complete after oral dosing, with urinary excretion of unchanged drug as the predominant route of elimination in humans...
  7. ncbi Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine
    Min Zhu
    Research and Development, Bristol Myers Squibb, P O Box 4000, Princeton, NJ 08543 4000, USA
    Antimicrob Agents Chemother 53:2346-53. 2009
    ..With this model-based analysis, efavirenz exposures can be projected prior to and at the steady state of induction, allowing a better understanding of the time course and magnitude of enzyme induction...
  8. ncbi Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin
    Bharat D Damle
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    Antimicrob Agents Chemother 46:385-91. 2002
    ....
  9. ncbi The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease
    Jing-He Yan
    Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA
    J Clin Pharmacol 45:434-45. 2005
    ..5 mg/kg/day) for SCD patients with CL(cr) <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment...
  10. ncbi Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole
    B Damle
    Clinical Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA
    Biopharm Drug Dispos 23:59-66. 2002
    ....
  11. ncbi Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects
    B K Malhotra
    Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA
    J Clin Pharmacol 41:833-41. 2001
    ..Extrahepatic organs may be involved in the elimination of omapatrilat. Plasma concentrations of omapatrilat exhibit a prolonged terminal elimination phase, which represents elimination from a deep compartment...